Found: 23
Select item for more details and to access through your institution.
Up-regulated exosomal miRNA-140-3p in CML patients with musculoskeletal pain associated with discontinuation of tyrosine kinase inhibitors.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Sustained complete cytogenetic remission in a patient with chronic myeloid leukemia after discontinuation of imatinib mesylate therapy.
- Published in:
- 2007
- By:
- Publication type:
- Case Study
Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib.
- Published in:
- International Journal of Molecular Sciences, 2016, v. 17, n. 4, p. 570, doi. 10.3390/ijms17040570
- By:
- Publication type:
- Article
Tyrosine Kinase Inhibitors Do Not Promote a Decrease in SARS-CoV-2 Anti-Spike IgG after BNT162b2 Vaccination in Chronic Myeloid Leukemia: A Prospective Observational Study.
- Published in:
- Vaccines, 2022, v. 10, n. 9, p. 1404, doi. 10.3390/vaccines10091404
- By:
- Publication type:
- Article
Targeting phosphoinositide 3-kinases and histone deacetylases in multiple myeloma.
- Published in:
- Experimental Hematology & Oncology, 2021, v. 10, n. 1, p. 1, doi. 10.1186/s40164-021-00213-6
- By:
- Publication type:
- Article
Combining the ABL1 Kinase Inhibitor Ponatinib and the Histone Deacetylase Inhibitor Vorinostat: A Potential Treatment for BCR-ABL-Positive Leukemia.
- Published in:
- PLoS ONE, 2014, v. 9, n. 2, p. 1, doi. 10.1371/journal.pone.0089080
- By:
- Publication type:
- Article
Copanlisib, a novel phosphoinositide 3-kinase inhibitor, combined with carfilzomib inhibits multiple myeloma cell proliferation.
- Published in:
- Annals of Hematology, 2019, v. 98, n. 3, p. 723, doi. 10.1007/s00277-018-3547-7
- By:
- Publication type:
- Article
Efficacy of MK-0457 and in combination with vorinostat against Philadelphia chromosome positive acute lymphoblastic leukemia cells.
- Published in:
- Annals of Hematology, 2010, v. 89, n. 11, p. 1081, doi. 10.1007/s00277-010-0998-x
- By:
- Publication type:
- Article
Therapeutic targeting of PFKFB3 and PFKFB4 in multiple myeloma cells under hypoxic conditions.
- Published in:
- Biomarker Research, 2022, v. 10, n. 1, p. 1, doi. 10.1186/s40364-022-00376-2
- By:
- Publication type:
- Article
Relevance of diffusion-weighted imaging with background body signal suppression for staging, prognosis, morphology, treatment response, and apparent diffusion coefficient in plasma-cell neoplasms: A single-center, retrospective study.
- Published in:
- PLoS ONE, 2021, v. 15, n. 7, p. 1, doi. 10.1371/journal.pone.0253025
- By:
- Publication type:
- Article
Effect of asciminib and vitamin K2 on Abelson tyrosine-kinase-inhibitor-resistant chronic myelogenous leukemia cells.
- Published in:
- BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-11304-4
- By:
- Publication type:
- Article
Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells.
- Published in:
- Cancer Cell International, 2013, v. 13, n. 1, p. 1, doi. 10.1186/1475-2867-13-32
- By:
- Publication type:
- Article
Vitamin K2 sensitizes the efficacy of venetoclax in acute myeloid leukemia by targeting the NOXA-MCL-1 pathway.
- Published in:
- PLoS ONE, 2024, v. 19, n. 7, p. 1, doi. 10.1371/journal.pone.0307662
- By:
- Publication type:
- Article
Effect of dual inhibition of histone deacetylase and phosphatidylinositol-3 kinase in Philadelphia chromosome-positive leukemia cells.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Membranous glomerulonephritis with nephrotic syndrome associated with chronic lymphocytic leukemia.
- Published in:
- 2000
- By:
- Publication type:
- journal article
Anti-leukemic activity of axitinib against cells harboring the BCR-ABL T315I point mutation.
- Published in:
- Journal of Hematology & Oncology, 2015, v. 8, n. 1, p. 1, doi. 10.1186/s13045-015-0190-9
- By:
- Publication type:
- Article
Anti-leukemic activity of axitinib against cells harboring the BCR-ABL T315I point mutation
- Published in:
- Journal of Hematology & Oncology, 2015, v. 8, n. 1, p. 97, doi. 10.1186/s13045-015-0190-9
- By:
- Publication type:
- Article
Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells.
- Published in:
- Journal of Hematology & Oncology, 2014, v. 7, n. 1, p. 1, doi. 10.1186/1756-8722-7-37
- By:
- Publication type:
- Article
WEE1 and PARP-1 play critical roles in myelodysplastic syndrome and acute myeloid leukemia treatment.
- Published in:
- Cancer Cell International, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12935-023-02961-3
- By:
- Publication type:
- Article
Potential of a sphingosine 1-phosphate receptor antagonist and sphingosine kinase inhibitors as targets for multiple myeloma treatment.
- Published in:
- Oncology Letters, 2022, v. 23, n. 4, p. N.PAG, doi. 10.3892/ol.2022.13231
- By:
- Publication type:
- Article
The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1.
- Published in:
- Cancer Science, 2009, v. 100, n. 5, p. 970, doi. 10.1111/j.1349-7006.2009.01131.x
- By:
- Publication type:
- Article
Activity of a novel Aurora kinase inhibitor against the T315I mutant form of BCR-ABL: In vitro and in vivo studies.
- Published in:
- Cancer Science, 2008, v. 99, n. 6, p. 1251, doi. 10.1111/j.1349-7006.2008.00810.x
- By:
- Publication type:
- Article
Combination of an aurora kinase inhibitor and the ABL tyrosine kinase inhibitor asciminib against ABL inhibitor-resistant CML cells.
- Published in:
- Medical Oncology, 2024, v. 41, n. 6, p. 1, doi. 10.1007/s12032-024-02394-6
- By:
- Publication type:
- Article